Research published in this month's Journal of Clinical Oncology found that pre-op MRI assessment is crucial in helping to inform a more advanced treatment approach for rectal patients by predicting local recurrence and disease-free survival.Rectal cancer currently accounts for one third of all colorectal cancers and is a leading cause of cancer death in the Western World.
Breast cancer drug halves cases in high-risk women
12/13/2013
A large landmark study funded by Cancer Research UK has found that the breast cancer drug anastrozole can halve the chances of developing the disease in high-risk women.
The function of two tumor-suppressing genes could play a vital role in helping to control obesity and other diseases such as diabetes, heart disease and cancer, according to researchers in Temple University's Sbarro Institute for Cancer Research and Molecular Medicine.
One step closer to understanding a deadly childhood brain cancer
12/13/2013
A new study by Canadian researchers may pave the way for more effective treatment of an aggressive and deadly type of brain tumour, known as ETMR/ETANTR. The tumour, which is seen only in children under four, is almost always fatal, despite aggressive treatment. The study proposes a new model for how this brain tumour develops and suggests possible targets to investigate for novel therapies.
In lower-risk breast cancer patients, Herceptin plus Taxol highly effective
12/13/2013
A remarkable 98.7 percent of certain lower-risk breast cancer patients were cancer free for at least three years after taking a combination of the drugs Herceptin and Taxol, a study has found.The study is the first major trial to examine the Herceptin-Taxol combination in patients who have a type of breast cancer with the biology known as small, node-negative, HER2+.
Highly effective treatment option identified for patients with HER2-positive breast cancer
12/13/2013
Combining the chemotherapy drugs docetaxel and carboplatin with the HER2-targeted therapy trastuzumab was identified to be an ideal postsurgery treatment option for patients with HER2-positive breast cancer, regardless of tumor size and whether or not disease has spread to the lymph nodes, according to results from the BETH study presented at the 2013 San Antonio Breast Cancer Symposium, held Dec.
6-million-euro European study to combat bowel cancer
12/13/2013
Queen's University has announced it is to lead a €6 million European study to find new treatments for bowel cancer.The research, which involves 13 partners in eight different European countries, will look at two major genetic factors which make bowel cancer difficult to treat.Bowel cancer, also known as colorectal cancer, is the second major cause of cancer mortality.
'No serious heart risks' linked to smoking cessation therapies
12/13/2013
The American Heart Association claims that three different types of smoking cessation therapies do not pose serious heart risks, quashing concerns that certain products may increase the risks of heart attack, stroke or heart-related death.
Genetic signature identifies patients with more aggressive triple-negative cancers
12/13/2013
A new test has the potential to help physicians identify patients with the most lethal forms of triple-negative breast cancer, a disease which requires aggressive and innovative treatment.
Identifying aggressive breast cancers in black women
12/13/2013
African-American women who get breast cancer often get more aggressive forms of the disease and at younger ages than other women.But a Georgia State University researcher has found a way to identify these aggressive cancers in black women, which would let their doctors customize their treatment.Ritu Aneja, associate professor of biology, has been studying a protein called HSET.